Induration at or near injection site: Case definition and guidelines for collection, analysis, and presentation of immunization safety data
Katrin Kohl(Centers for Disease Control and Prevention), Frederick Varricchio(Rutgers, The State University of New Jersey), Paul T. Heath(St George's, University of London), Sandra Jo Hammer(California Department of Public Health), Scott A. Halperin(Dalhousie University), Anne Schuind(GlaxoSmithKline (United States)), Edward Rothstein, L. Ball(Center for Biologics Evaluation and Research), Wikke Walop(Public Health Agency of Canada), Renald Hennig(Novartis (Germany)), Jane Gidudu(The Centers)
Cited by 26
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Second symposium on the definition and management of anaphylaxis: Summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium
|Journal of Allergy and Clinical Immunology|2006|2.3k
Second Symposium on the Definition and Management of Anaphylaxis: Summary Report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium
|Annals of Emergency Medicine|2006|747
Infant Group B Streptococcal Disease Incidence and Serotypes Worldwide: Systematic Review and Meta-analyses
|Clinical Infectious Diseases|2017|453